A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.
Experimental Treatment Acquiring Popularity Online
The experimental drug, which is still in clinical trials, is being promoted by social media influencers for its supposed fat-burning properties. Followers are urged to contact these accounts privately for supplier links, while also receiving promotional offers.
Thriving Commerce on Messaging Platforms
Separately, a flourishing trade exists on messaging services, where communities with thousands of participants share “before and after” images, administration instructions and claims of rapid UK delivery. Vendors market the drug there before directing customers to other platforms for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injection created by US drugmaker Eli Lilly. The treatment targets three gut hormones – GLP-1, GIP and glucagon. Preliminary studies suggest it could help individuals reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the successor to Ozempic.
Medical Experts Voice Concerns
However, physicians and pharmacists have warned that the distribution of what remains an unlicensed medication in the United Kingdom is worrisome and could result in individuals administering substances of uncertain source.
Several experts said the demand for retatrutide could be linked to the rising cost of licensed weight loss treatments such as Mounjaro.
Legal Status and Implementation
Marketing retatrutide on social media or Telegram is prohibited in the UK, as it is an unlicensed drug that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.
Several content creators attempt to circumvent the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and supply can still violate pharmaceutical, marketing, and customer regulations, risking penalties, legal action or imprisonment.
Platform Response and Content Removal
Based on TikTok, the service has taken down problematic content and prohibited associated keywords and search suggestions. The company stated it was dedicated to keeping the platform safe and allocating resources in enhancing compliance measures.
Online Marketplace Activities
Research also discovered communities with up to 9,000 participants selling the experimental drug using Telegram's integrated discovery tool, which functions like a online catalog. Typing “retatrutide” immediately displays groups with thousands of members, populated with images of weight loss, positive testimonials and step-by-step guides for mixing or administering at home.
Within moments of entering one group, a seller posted contact information, where the majority of transactions take place. The vendor sent an guidebook and guaranteed shipping within 48 hours. When questioned whether the substance was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. None inquired about weight, health issues or past usage.
Product Information and Pricing
Within these communities, messages show dark colored packages with postal service labels, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, prepared at home with purified liquid, or pre-filled pens usually priced at £160 for 20 milligrams. When questioned how much time a pen should last, sellers give conflicting answers ranging from a several days to “depends on your body”.
Service Oversight and Safety Measures
A representative for the messaging service stated it regularly monitored dangerous material on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“People are administering materials they can’t verify. Although the research behind this drug is sound, these online versions may not contain what they advertise,” stated Jason Murphy, the director of pharmacy at Chemist4U.
A medical professional of Asda Online Doctor linked the increase in demand to current cost increases for authorized slimming medications such as Mounjaro. “With costs increasing, patients are using online platforms. But counterfeit injections are highly risky. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.
Her staff has previously encountered patients harmed by self-injection from unconfirmed sources. “We recognize the frustration, but purchasing from Telegram or WhatsApp is gambling with your well-being,” said Wyllie. “These materials could be impure or improperly measured.”
Producer Statement
A representative from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a Lilly experimental product not yet authorized … may expose patients to potentially serious health risks”.
